May 6, 2015
Target-specific oral anticoagulants have emerged as alternative therapeutic options for the management of thrombembolic disorders.
Before the development of target-specific oral anticoagulants (TSOACs), the oral vitamin K antagonist warfarin was the mainstay of treatment and prophylaxis for thromboembolism. Although effective, the use of oral vitamin K antagonists requires routine laboratory monitoring, owing to their narrow therapeutic index, slow onset of action, and potential for multiple drug-drug and food interactions. Frequent laboratory monitoring and dose adjustment result in poor patient compliance and difficulty maintaining patients within a therapeutic window. These limitations led to the development of TSOACs (see Table 1).